clinical trial · NCT06433128
Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections
Basilea Pharmaceutica·—·available
Invasive Fungal InfectionsFosmanogepix solution for infusionFosmanogepix 400 mg tablets
brief summary
The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.
started
—
primary completion
—
completion
—
last updated
Jul 24, 2025
official title
Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections Who Have no Other Treatment Options
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol